Clinical Takeaway
In this phase 3 randomized controlled trial, 820 adults with chronic low back pain received either VER-01, a full-spectrum cannabis extract, or placebo over a 12-week double-blind period, followed by longer-term open-label and withdrawal phases. The trial design meets the highest standard of clinical evidence and directly addresses the well-documented gap in safe, effective treatment options for one of the most prevalent pain conditions globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant adverse effect profiles. The large sample size (n=820) and robust trial design including extended open-label follow-up strengthen the clinical applicability of findings regarding VER-01’s efficacy and safety profile. These results could inform evidence-based treatment algorithms for CLBP management and potentially reduce opioid and NSAID dependence in this population.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial adds meaningful data to the limited RCT evidence for cannabis-based medicines in chronic low back pain, a condition where conventional pharmacotherapy remains suboptimal. While the enrollment of 820 participants and rigorous double-blind design strengthen the findings, clinicians should consider several important caveats: the generalizability of results from a single cultivar (DKJ127) to other cannabis products remains unclear, the full therapeutic profile across diverse patient phenotypes and comorbidities requires further characterization, and long-term safety data beyond the study duration warrants attention. The incomplete abstract prevents assessment of effect size, clinically meaningful response rates, and comparative efficacy relative to established alternatives, which limits interpretation at this stage. If VER-01 demonstrates robust pain reduction with a favorable safety profile, it could serve as a reasonable option for selected patients with CLBP who have failed or are intolerant to first-line therapies, though individualized assessment of cannabinoid interactions and careful patient selection remain